Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2024 May;197:104328. doi: 10.1016/j.critrevonc.2024.104328. Epub 2024 Mar 13
2024
AOU Città della Salute di Torino
ASL Torino 4
AOU San Luigi di Orbassano
Tipo pubblicazione
Review
Autori/Collaboratori (9)Vedi tutti...
Di Maio M
Department of Oncology, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy.
Novello S
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
Sperone P
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
et alii...
Abstract
In recent years, cancer research has highlighted the role of disrupted microbiota in carcinogenesis and cancer recurrence. However, microbiota may also interfere with drug metabolism, influencing the efficacy of cancer drugs, especially immunotherapy, and modulating the onset of adverse events. Intestinal micro-organisms can be altered by external factors, such as use of antibiotics, proton pump inhibitors treatment, lifestyle and the use of prebiotics or probiotics. The aim of our review is to provide a picture of the current evidence about preclinical and clinical data of the role of gut and local microbiota in malignancies and its potential clinical role in cancer treatments. Standardization of microbiota sequencing approaches and its modulating strategies within prospective clinical trials could be intriguing for two aims: first, to provide novel potential biomarkers both for early cancer detection and for therapeutic effectiveness; second, to propose personalized and "microbiota-tailored" treatment strategies.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 38490281
DOI : 10.1016/j.critrevonc.2024.104328
Keywords
Microbiota; Immunotherapy; Immune checkpoint inhibitors; Biomarker; Cancers; Prebiotics/administration & dosage; Probiotics/therapeutic use; Microbiota/drug effects; Gastrointestinal Microbiome/drug effects; Neoplasms/microbiology/therapy; Humans;